Key Points:
- ResMed achieved a 9% revenue increase in the Americas after securing an exemption from trade tariffs.
- The $43 billion Australian medical company bypassed the 10% levy thanks to the international Nairobi Protocol treaty.
- Chief Executive Officer Mick Farrell dismissed fears that weight loss drugs like Ozempic would hurt future sales.
- Despite posting an 11% overall revenue bump, the company’s stock price fell 3.2% on Friday.
Australian medical giant ResMed is seeing massive success in the United States. The company, which makes sleep apnea masks and breathing machines, managed to avoid strict trade tariffs imposed by President Donald Trump. This clever legal maneuver helped the business significantly increase its profits in the American market during the first three months of 2026. The company stands out as a rare winner amid intense global trade disputes.
Mick Farrell serves as the chief executive officer of the $43 billion healthcare company. On Friday, he shared exciting financial updates with his investors. Farrell confirmed that revenue for the company skyrocketed by 9% across the Americas compared with the same period last year. He pointed specifically to the masks and accessories category, noting that it showed incredible growth over the winter months.
The chief executive explained why sales keep climbing. Customers simply keep coming back to buy more masks and replacement parts to maintain their daily therapy. People rely on continuous positive airway pressure machines, commonly known as CPAPs, to breathe safely while they sleep. When patients feel the positive effects of the therapy, they eagerly spend more money to replace their old equipment and stay healthy.
ResMed dodged a major financial bullet back in April 2025. The company announced that its life-saving medical devices qualified for a full exemption from the heavy American trade levies. The business used a special international agreement, the Nairobi Protocol, to avoid the high taxes. This important global treaty guarantees that countries will not charge import duties on products designed to help people with disabilities or chronic medical conditions.
This exemption matters because the United States still charges a strict 10% tariff on goods imported from Australia. This specific tax remains in effect today, even though the Supreme Court struck down several similar trade rules in February. Farrell told investors last year that federal authorities agreed with their legal argument. The government recognized that patients rely heavily on these respiratory devices, so it kept them free from the costly global tariff disputes that hurt other consumer industries.
Because the American market looks so promising, ResMed decided to invest more money directly in the country. The company recently revealed big plans to double its physical manufacturing footprint inside the United States. Executives plan to open a brand new production facility in California to keep up with the soaring demand for their medical equipment. Building masks locally will help the company deliver products faster and secure its supply chain against future global shipping delays.
However, the company faced some tough questions from worried financial analysts this quarter. Many investors feared that the massive popularity of new weight loss drugs, like Ozempic, would destroy the sleep apnea business. Doctors link sleep apnea closely to obesity. Therefore, some financial experts assumed that patients who lost massive amounts of weight with these medications would no longer need to buy breathing masks.
Farrell quickly shut down these negative rumors. He told reporters and investors that the rapid rise in weight-loss medications actually helps his company make more money. He boldly stated that anyone calling these drugs a problem for the business is completely wrong. Instead of seeing the medication craze as a dangerous roadblock, he views it as a powerful tailwind pushing his company forward.
The chief executive explained the science behind this surprising consumer trend. When doctors prescribe weight loss drugs alongside traditional CPAP breathing machines, patients experience incredible health outcomes. Farrell noted that patients using this combination therapy show much higher initial rates of sleep treatment. The drugs motivate patients to address all of their health issues at the same time.
The data proves that these patients stick with their breathing therapy much longer. Farrell highlighted that combination users show higher adherence rates after one full year of continuous use. Furthermore, they continue to buy and use the masks at higher rates even three years later. The medication simply encourages patients to take their overall health much more seriously, which translates into steady sales for the medical company.
Despite all this positive news and strong sales data, Wall Street reacted poorly. The company reported an impressive 11% global revenue bump, but some investors were still disappointed with the quarterly earnings report. As a result, ResMed’s shares fell 3.2% by the end of trading on Friday. The solid sales growth and clever tariff exemptions simply could not convince every investor that the stock was worth holding for the long term.
